Perspective Therapeutics Inc Stock Price, News & Analysis

Perspective Therapeutics (NYSE AMERICAN: CATX) said senior leadership will participate in two investor conferences in early December 2025.

Events: Piper Sandler 37th Annual Healthcare Conference fireside chat on Dec 2, 2025 at 1:00–1:25 p.m. ET in New York, and Evercore 8th Annual Healthcare Conference fireside chat on Dec 3, 2025 at 3:00–3:20 p.m. ET in Miami. Management will also be available for one-on-one investor meetings.

Perspective Therapeutics (NYSE AMERICAN: CATX) reported 3Q 2025 results and a business update on Nov 10, 2025, highlighting clinical progress and balance sheet status.

Key clinical points: updated interim [212Pb]VMT-α-NET data (DCO Sep 12, 2025) showed favorable safety in 55 treated patients with no DLTs or Grade 4–5 TEAEs and investigator-assessed responses in Cohort 2; Cohort 3 (6.0 mCi) opened June 2025 with eight patients dosed. VMT01 and PSV359 continue early-stage dosing and site activations.

Financials: cash and short-term investments ~$174M at Sep 30, 2025, expected to fund operations into late 2026; R&D and operating expenses rose materially year‑over‑year, driving a wider net loss.

Perspective Therapeutics (NYSE AMERICAN: CATX) said senior leadership will attend investor meetings at two November 2025 conferences.

Meetings include one-on-one meetings at the Truist Securities BioPharma Symposium on Thursday, November 6, 2025 in New York, and a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 11, 2025 from 4:15–4:50 p.m. ET in Palm Beach, Florida.

Perspective Therapeutics (NYSE AMERICAN: CATX) will report its third quarter 2025 financial results and provide a business update on Monday, November 10, 2025 after the market closes.

The company said the related press release will be published on its newsroom at https://perspectivetherapeutics.com/newsroom/press-releases.

Perspective Therapeutics (NYSE: CATX) reported updated interim Phase 1/2a results for [212Pb]VMT-α-NET with a data cut-off of Sept 12, 2025, presented at ESMO 2025.

Key findings: 55 patients received at least one dose; no dose limiting toxicities or treatment-related discontinuations; Objective Response Rate 44% (7/16) in Cohort 2 patients with SSTR2 expression in all tumors at a median follow-up of 41 weeks; 14 of 16 such patients (87.5%) were progression-free and on study. Additional interim efficacy data for 23 Cohort 2 and 8 Cohort 3 patients are expected in 2026. Preliminary cash was $174.1M as of Sept 30, 2025, projected to fund operations into late 2026. A webcasted conference call was held on Oct 20, 2025 at 8:30 AM ET.

Perspective Therapeutics (NYSE AMERICAN: CATX) has announced the dosing of the first patient in the second cohort of its Phase 1/2a clinical trial for [212Pb]PSV359. The study is evaluating the safety and preliminary anti-tumor activity in patients with FAP-α positive solid tumors.

The second cohort patients will receive 5.0 mCi of [212Pb]PSV359 for up to four doses every eight weeks, an increase from the 2.5 mCi dose in the first cohort. The dose escalation was recommended by the Safety Monitoring Committee following their review of two patients from the initial cohort.

Patient selection is conducted through SPECT imaging with [203Pb]PSV359. The treatment targets FAP-α, which is present in various epithelial malignancies including pancreatic cancer, colorectal cancer, and sarcomas.

Perspective Therapeutics (NYSE AMERICAN: CATX) announced progress in its Phase 1/2a clinical trial for [212Pb]VMT01, a targeted alpha-particle therapy for metastatic melanoma. The company has dosed the first patient with a higher dose of 3.0 mCi in combination with Bristol Myers Squibb's nivolumab (Opdivo®).

The advancement follows the Safety Monitoring Committee's review of encouraging results from previous cohorts, including five patients treated with 1.5 mCi monotherapy and two patients receiving the combination therapy at 1.5 mCi. Additionally, the company has reopened enrollment for the 3.0 mCi monotherapy cohort.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, has appointed Joel Sendek as Chief Financial Officer, effective September 4, 2025. Sendek brings significant experience as a biotech CFO and Wall Street analyst, having previously served as CFO at Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma.

As CFO, Sendek has successfully raised over $2.5 billion in corporate transactions. His background includes leadership roles at Stifel, Lazard, and Oppenheimer, where he earned Wall Street Journal recognition as an All-Star Analyst with a #1 ranking in stock picking. He succeeds Juan Graham in the role.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, has appointed Maya Martinez-Davis as an independent director to its Board of Directors. Martinez-Davis currently serves as President of GSK's U.S. Commercial business and brings extensive experience in oncology and biopharma from previous executive roles at Merck KGaA and Pfizer.

The appointment strengthens Perspective's board as the company advances its three clinical-stage programs in the radiopharmaceutical field. Martinez-Davis's expertise in commercial and clinical development in oncology aligns with the company's focus on developing alpha-emitting radioisotope treatments for various cancers.